retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial is a triple-agonist drug targeting GLP-1, GIP, and receptors to suppress appetite and boost thermogenesis. trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Weight Loss Blog – Maryland

GLP-1 release is triggered when nutrientsparticularly carbohydrates, fats, and proteinscome into contact with L-cells in the intestine

You actually could replace your entire protein intake with undenatured whey protein, and derive a benefit from it, assuming you were extremely ill and needed a lot of glutathione

Studies have suggested that GLP-1Ra may reduce inflammation through multiple pathways and may be beneficial in reducing kidney disease independent of the presence of diabetes

Understanding your genetic predisposition to GLP-1 side effectsincluding sleep sensitivityallows your provider to proactively manage your treatment from day one

So, it may play a role in conditions such as Alzheimer's disease and stroke